Jeff Geschwind, MD

Dr. Jeff Geschwind earned his Medical Degree from Boston University School of Medicine, completed his residency training in Diagnostic Radiology at the University of California at San Francisco as a Resident-Scholar sponsored by the National Institutes of Health (NIH) and carried out his fellowship training in Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine.  He is the former Director of the Division of Vascular and Interventional Radiology at the Johns Hopkins University School of Medicine, where he was also Professor of Radiology, Surgery, and Oncology and Chairman of Radiology and Biomedical Imaging at Yale School of Medicine.

Dr. Geschwind has published nearly 300 scientific manuscripts (Google Scholar H-Index 75), wrote the first textbook dedicated to Interventional Oncology, co-edited the textbook of reference in Interventional Radiology, namely, Abram’s Angiography, and was the lead or co-investigator on more than 50 clinical trials testing innovative treatments for patients with liver cancer. He is recognized internationally as an expert and key opinion leader in liver cancer, more generally the new field of Interventional Oncology. In addition, Dr. Geschwind has expertise and vast clinical experience in oncology, interventional radiology (including vascular and non-vascular interventions), liver diseases, imaging science, immune-oncology, tumor metabolism, and drug-device combination.

Dr. Geschwind has received numerous national and international awards throughout his career, including, the Annual Memorial Award from the Association of University Radiologists, the Alexander Margulis Award for Excellence in Research, the Society of Interventional Radiology Gary Becker Young Investigator Award, the American Society of Clinical Oncology Merit Award, the American Roentgen Ray Society Fellowship Award, the Boston University School of Medicine and the University of California San Francisco Department of Radiology Alumni Award, the Ernest Ring Academic Development Program from the Society of Interventional Radiology and the Wilhelm Conrad Roentgen Honorary Award from the European Society of Radiology. Most recently, he was recognized by Marquis Who’s Who organization for his scientific accomplishments during his career and awarded the Albert Nelson Marquis Lifetime Achievement Award. In 2012, he was inducted into the Academy of Radiology Research from the Radiology Society of North America, the highest recognition for radiologists. He is Board-Certified in Radiology.

CORE COMPETENCIES

• Current member of Editorial Board of “Diagnostics”, “Frontiers in Oncology”, and “Gastroenterology Insights”
• Former member of the editorial board of scientific journals, including “Radiology, Cardiovascular and Interventional Radiology, Journal of Vascular and Interventional Radiology,” “Anticancer Research”
• Providing journal reviews for various medical journals such as Lancet, Cancer Research, Hepatology, Journal of Hepatology, Cardiovascular and Interventional Radiology, and Journal of Clinical Oncology
• Visiting professorships, lectures and keynote speeches including named lectures (among others): NIH John Doppman Memorial Lecture for Imaging Sciences, Memorial Sloan Kettering Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, the University of Michigan, Georgetown University, Brown University, Yonsei University, Seoul National University, Malaysia Cancer Center, and the Chinese University of Hong Kong
• Recognized as a Top Doctor by US News and World Report
• Diplomate of the American Board of Radiology since 1998
• Providing advice regarding preclinical and clinical strategy to companies
• Acting as fractional CMO for various companies in my areas of expertise
• Acting as a board member and/or medical advisor
• Setting up medical advisory boards
• Building clinical teams
• Developing preclinical and clinical strategy for novel and established high-risk medical devices for global market release

RECENT PROJECTS

• Prepared clinical and regulatory strategies as well as clinical evaluation reports for:
  • Cryoablation for breast cancer
  • Endobronchial therapy for lung cancer
  • Intraarterial therapy using radioactive microspheres for liver cancer
  • Noninvasive ultrasound-guided therapy for liver and kidney cancer
  • Tools to help visualize breast cancer
  • Treatment of solid tumors using filtration of exosomes
  • Liver assist to preserve liver organs before liver transplant
  • Imaging of carotid arteries using CT and MR angiography

PUBLICATIONS*

• Korn R, Burkett A, Geschwind JF, Zygadlo D, Brodie T, Cridebring D, Von Hoff D, and Demeure M.  Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma? Diagnostics, 2023 Mar; 13(5): 941. Published online 2023 Mar 1. doi: 10.3390/diagnostics13050941
• Geschwind JF, and Nezami N.  Combining Chemotherapy and Radiation Therapy for Liver Cancer: Is the Solution an Intraarterial Approach?  Cardiovasc Intervent Radiol. 2020 Oct;43(10):1538-1539. doi: 10.1007/s00270-020-02592-5. Epub 2020 Aug 11. PMID: 32783143
• Nezami N, Geschwind JF.  Predicting Patient Survival in Oncology: Is it Time to Take a New Path?  Cardiovasc Intervent Radiol. 2020 Aug;43(8):1173-1174. doi: 10.1007/s00270-020-02553-y. PMID: 32529335
• van Breugel JMM, Geschwind JF, Mirpour S, Savic LS, Zhang X, Duran R, De Lin M, Miszczuk M, Liapi E, and Chapiro J.  Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019; 9(13): 3674-3686. doi: 10.7150/thno.32943
• Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.  J Vasc Interv Radiol. 2018 Jun;29(6):850-857.e1. doi: 10.1016/j.jvir.2018.01.769. Epub 2018 Mar 14.  PMID: 29548875
• Zhao Y, Duran R, Bai W, Sahu S, Wang W, Kabus S, Lin M, Han G, Geschwind JF.  Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?  Cardiovasc Intervent Radiol. 2017 Oct 30. doi: 10.1007/s00270-017-1829-4. PMID: 29086058
• Adam LC, Murali N, Chapiro J, Geschwind JF.  Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet? Radiology. 2017 Nov;285(2):333-335. doi: 10.1148/radiol.2017171527.  PMID: 29045226
• Savic LJ, Chapiro J, Geschwind JF. Science to Practice: Killing Dormant Cells-Is Targeting Autophagy the Key to Complete Tumor Response in Transarterial Chemoembolization? Radiology. 2017 Jun;283(3):621-623. doi: 10.1148/radiol.2017170358.  PMID: 28514219
• Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF.  The impact of antiangiogenic therapy combined with  Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma.  Clin Imaging. 2017 Jun 7;46:1-7. doi: 10.1016/j.clinimag.2017.05.007. PMID: 28668723.
• Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF.  Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.  Eur Radiol. 2017 Dec;27(12):4995-5005. doi: 10.1007/s00330-017-4856-2. Epub 2017 Jul 4.  PMID: 28677067.
• Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J. 2016 Nov/Dec;22(6):365-372. PMID: 27870678
• Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response.  Expert Rev Anticancer Ther. 2017 Feb;17(2):119-127. doi: 10.1080/14737140.2017.1273775. Epub 2016 Dec 27. Review. PMID: 27983883
• Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of Hepatocellular Carcinoma.  Med Oncol. 2017 Apr;34(4):58. doi: 10.1007/s12032-017-0917-2. Epub 2017 Mar 16. PMID: 28299645
• Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2016 Nov 12. pii: S1542-3565(16)31049-7. doi: 10.1016/j.cgh.2016.10.036. PMID: 27847278
• Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?  Radiology. 2017 Jun;283(3):883-894. doi: 10.1148/radiol.2016160838. Epub 2016 Nov 10.  PMID: 27831830

*among 290 published articles